FinscoFinsco

AnaptysBio (US.ANAB)

Capital Allocation Audit · Period: 2013 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.ANAB · YoY: 2026 Q1 vs 2025 Q1

MetricValueYoY
FCF Conversion100.1%→
ROE-414.9%↓
Cash Conversion-→
D/E Ratio1.07↓
Gross Margin0.0%↓
US.ANAB (AnaptysBio) | YoY: 2026 Q1 vs 2025 Q1


Metric             Value  YoY
-----------------------------
FCF Conversion    100.1%    →
ROE              -414.9%    ↓
Cash Conversion        -    →
D/E Ratio           1.07    ↓
Gross Margin        0.0%    ↓
Key Metrics
US.ANAB (AnaptysBio) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY
-----------------------------
FCF Conversion 100.1% →
ROE -414.9% ↓
Cash Conversion - →
D/E Ratio 1.07 ↓
Gross Margin 0.0% ↓

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies